Home/Pipeline/DeTIL-0255

DeTIL-0255

Solid Tumors

PreclinicalResearch

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Research

Company

Nurix Therapeutics

About Nurix Therapeutics

Nurix Therapeutics is focused on discovering, developing, and commercializing small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Its core DELigase platform integrates expertise in E3 ligases, ubiquitination, and medicinal chemistry to create targeted protein degraders and inhibitors. The company has established strategic collaborations with major pharmaceutical partners like Gilead and Sanofi, and is progressing a robust pipeline of drug candidates, including its lead BTK degrader NX-5948 and CBL-B inhibitor NX-1607, through clinical development.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active